Two new co-crystals, Ticagrelor with Nicotinamide, have been prepared with improved solubility. Because Ticalegor has a poor solubility and dissolution rate, a novel co-crystallization method with structurally homogenous crystalline material, an active pharmaceutical ingredient (API), and co-former indefinite stoichiometric amount has been made to improve Ticagrelor’s solubility. The co-crystal of Ticagrelor (TICA) with Nicotinamide (NCA) was prepared in ratio (1:1) and confirmed by FTIR, DSC, and XRD characterization. Furthermore, the single crystal structure of TICA-NCA hydrate was analyzed. The solubility of co-crystals was investigated in pH 2 acidic medium, which was a significant improvement as compared to the solubility of a free drug. The in vitro dissolution rate of co-crystal was larger than that of the commercial product.

No abstract

Puerarin (PUE) is a Chinese traditional medicine known to enhance glucose uptake into the insulin cells to downregulate the blood glucose levels in the treatment of type II diabetes. Nevertheless, the bioavailability of pristine PUE is limited due to its poor solubility and low intestinal permeability. In this work, we demonstrate that the solubility of PUE can be significantly enhanced via its co-crystallization with L-Proline (PRO). Two crystalline phases, namely, the solvate-free form [PUE][PRO] (I) and the solvated form [PUE]2[PRO]∙EtOH∙(H2O)2 (II) are isolated. These two phases are characterized by single-crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), Fourier-transformed infrared (FT-IR) spectra, nuclear magnetic resonance (NMR), and thermogravimetric analysis in association with differential scanning calorimetry (TGA-DSC). The solubility and dissolution rate of both I and II in water, gastrointestinal tract at pH 1.2, and phosphate buffer at pH 6.8 indicates a nearly doubled increase as compared to the pristine PUE. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of pristine PUE, I and II against murine colon cancer cell lines CT-26 and human kidney cell lines HEK-293 indicated that neither compound exhibits obvious cytotoxicity after 24 h. This work showcases that the readily available and biocompatible PRO can be a promising adjuvant to enhance the physicochemical properties of PUE toward orally administered drug formulation with improved pharmacokinetics.

Coprecipitation-adsorption plays a significant role during coagulation-flocculation-sedimentation (C/F/S) of antimony (Sb) in water. This work uses a Box–Behnken statistical experiment design (BBD) and response surface methodology (RSM) to investigate the effects of major operating variables such as initial Sb(III, V) concentration (100–1000 µg/L), ferric chloride (FC) dose (5–50 mg/L), and pH (4–10) on redox Sb species. Experimental data of Sb(III, V) removal were used to determine response function coefficients. The model response value (Sb removal) showed good agreement with the experimental results. FC showed promising coagulation behavior of both Sb species under optimum pH (6.5–7.5) due to its high affinity towards Sb species and low residual Fe concentration. However, a high dose of 50 mg/L of FC is required for the maximum (88–93%) removal of Sb(V), but also for the highest (92–98%) removal of low initial concentrations of Sb(III). Furthermore, BBD and RSM were found to be reliable and feasible for determining the optimum conditions for Sb removal from environmental water samples by a C/F/S process. This work may contribute to a better understanding and prediction of the C/F/S behavior of Sb(III, V) species in aqueous environments, to reduce potential risks to humans.

No abstract